Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure

• Type: Article in International Scientific Journal
• Date: 2015

Authors

Ferreira, JP (Author) FMUP; Santos, M (Author) Other; Oliveira, JC (Author) Other; Marques, I (Author) Other; Bettencourt P (Author) FMUP; Carvalho, H (Author) Other

Journal

Title: Arquivos Brasileiros de Cardiologia

Vol. 104

Pages: 308-313

ISSN: 0066-782X

Publisher: Sociedad Brasileira De Cardiologia

Indexing

ISI Web of Knowledge - 7 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-00G-4S5

DOI: 10.5935/abc.20140205

Abstract (EN): Background: Matrix metalloproteinases (MMPs) are a family of enzymes important for the resorption of extracellular matrices, control of vascular remodeling and repair. Increased activity of MMP2 has been demonstrated in heart failure, and in acutely decompensated heart failure (ADHF) a decrease in circulating MMPs has been demonstrated along with successful treatment. Objective: Our aim was to test the influence of spironolactone in MMP2 levels. Methods: Secondary analysis of a prospective, interventional study including 100 patients with ADHF. Fifty patients were non-randomly assigned to spironolactone (100 mg/day) plus standard ADHF therapy (spironolactone group) or standard ADHF therapy alone (control group). Results: Spironolactone group patients were younger and had lower creatinine and urea levels (all p < 0.05). Baseline MMP2, NT-pro BNP and weight did not differ between spironolactone and control groups. A trend towards a more pronounced decrease in MMP2 from baseline to day 3 was observed in the spironolactone group (-21 [-50 to 19] vs 1.5 [-26 to 38] ng/mL, p = 0.06). NT-pro BNP and weight also had a greater decrease in the spironolactone group. The proportion of patients with a decrease in MMP2 levels from baseline to day 3 was also likely to be greater in the spironolactone group (50% vs 66.7%), but without statistical significance. Correlations between MMP2, NT-pro BNP and weight variation were not statistically significant. Conclusion: MMP2 levels are increased in ADHF. Patients treated with spironolactone may have a greater reduction in MMP2 levels.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6